Former Kelly baseball standout Warner hopes to water ski in college

For the first time in 13 years, Preston Warner isn't playing baseball this summer.

Rather than standing on the pitcher's mound of a hot baseball diamond, the recent Kelly High School graduate is at the lake almost every day - water skiing.

Warner, a 6-foot-4 pitcher who throws an 89 mile per hour fastball, turned down seven partial Division I scholarship baseball offers, including a partial tuition offer from Lamar.

Instead, he'll attend college at Texas State, where he'll major in physical therapy. He's going there because it is his first choice of school.

He also hopes to earn a spot on the school's water skiing team - which won't be easy.

While water skiing is not an NCAA sport, it is highly competitive. Almost 150 schools compete in the National Collegiate Water Ski Association. Texas State, the school Warner will attend, was the 2011 national champion.

This is a lot less stressful than baseball for Warner. And he likes that it is an individual sport rather than a team sport like baseball.

"It's more easygoing and fun," Warner said. "It is nice to be able to go out and have fun with no stress at all. That's the biggest reason I do this."

Warner said wakeboarding is popular with many of his friends but he finds water skiing to be more challenging.

"With wakeboarding, it is a lot easier to plop yourself up," Warner said. "It takes more time to learn water skiing."

Warner is working with his uncle, Chuck Kalkbrenner, who still water skis competitively, almost every day at Kalkbrenner's private lake near Bridge City. Water skiers need a body of water with minimal wakes and debris for safety reasons.

There are three types of water skiing competitions - the slalom, tricks and jumping.

Warner is practicing in the slalom, where skiers wear one ski and must maneuver in and out of buoys.

A scoring matrix, influenced by the speed of the boat, the length of the rope and the number of buoys the skier goes through, determines the winner.

With baseball taking up much of Warner's time the last 13 years, he has a lot of catching up to do as a competitive water skier.

So far, Warner can successfully navigate around buoys while being pulled as fast as 32 miles per hour. To be ready for competition, he needs to be up to 36.

While Warner has come a long way, he still has a lot of improvement left to do.

"I'd say he still is at a beginner level," Kalkbrenner said. "I'd like to get him to the point where he can make the team (at Texas State)."

He finds his height helps him get around buoys without using as much rope as other competitors.

"I think he has a lot of potential," Kalkbrenner said. "We'll have him ready by the end of the summer."

Water skiing gives Warner a good workout - and requires more endurance than baseball, he said.

"It makes your arms burn, makes your legs burn," Warner said.

Even if he isn't as successful in water skiing as he was at baseball, he still has no regrets about his decision.

"I just kind of got tired of (baseball)," Warner said. "I had been doing it for so long. There were a lot of times when I was playing baseball that I wished I could have been out on the lake."

Source: http://www.beaumontenterprise.com/sports/hs/article/Former-Kelly-baseball-standout-Warner-hopes-to-3681788.php

soul train nevada caucus ufc 143 what time does the super bowl start ben gazzara nfl hall of fame 2012 ufc diaz vs condit

Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

[ Back to EurekAlert! ] Public release date: 4-Jul-2012
[ | E-mail | Share Share ]

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies.

About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although bone marrow stem cell transplantation is an option for some, patients without a matched donor have few treatment options. The findings of this new clinical study, carried out by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, suggest eltrombopag could be a second-line therapeutic option for them.

"Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia," will be published online July 5 in the New England Journal of Medicine.

Aplastic anemia is a rare blood disorder, with about 600 new cases in the U.S. each year. Aplastic anemia results from the destruction of bone marrow stem cells, which mature into red blood cells that carry oxygen, white blood cells that fight infection, and platelets that prevent excess bleeding. Symptoms of the disorder include fatigue, frequent infections, and hemorrhaging. In severe cases unresponsive to treatment, death can occur.

Eleven of 25 participants enrolled in this phase 2 study showed improved production of at least one type of blood cell (red blood cell, white blood cell, or platelet) after 12 weeks of oral eltrombopag therapy. Among the seven volunteers who continued taking the pills long-term (8-32 months), six eventually showed an improvement in all three types of blood cells, and were able to maintain safe blood counts without needing red blood cell or platelet transfusions. Overall the drug was well tolerated, with few side effects.

The research team in the NHLBI Hematology Branch tested eltrombopag because this drug had previously been shown to boost platelet levels in both healthy people and people with reduced platelets due to hepatitis C infection or immune thrombocytopenia, blood disorders that like aplastic anemia result in low platelet counts and increased risk of bleeding.

The encouraging finding in this study was improvement in red blood cell and white blood cell counts in some aplastic anemia patients, suggesting that the drug can stimulate bone marrow stem cells and perhaps have wider utility than initially predicted.

###

Learn more about this study at: http://clinicaltrials.gov/ct2/show/NCT00922883

Learn more about aplastic anemia at: http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/

Cynthia Dunbar, M.D., senior investigator in the NHLBI's Hematology Branch and a coauthor on the study, is available to comment on the study's findings and implications for future clinical studies with eltrombopag.

For Dr. Dunbar's complete bio, please visit: http://www.nhlbi.nih.gov/news/spokespeople/dunbar-cynthia.html

For more information or to schedule an interview, contact the NHLBI Communications Office at 301-496-4236 or nhlbi_news@nhlbi.nih.gov.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


[ Back to EurekAlert! ] Public release date: 4-Jul-2012
[ | E-mail | Share Share ]

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies.

About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although bone marrow stem cell transplantation is an option for some, patients without a matched donor have few treatment options. The findings of this new clinical study, carried out by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, suggest eltrombopag could be a second-line therapeutic option for them.

"Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia," will be published online July 5 in the New England Journal of Medicine.

Aplastic anemia is a rare blood disorder, with about 600 new cases in the U.S. each year. Aplastic anemia results from the destruction of bone marrow stem cells, which mature into red blood cells that carry oxygen, white blood cells that fight infection, and platelets that prevent excess bleeding. Symptoms of the disorder include fatigue, frequent infections, and hemorrhaging. In severe cases unresponsive to treatment, death can occur.

Eleven of 25 participants enrolled in this phase 2 study showed improved production of at least one type of blood cell (red blood cell, white blood cell, or platelet) after 12 weeks of oral eltrombopag therapy. Among the seven volunteers who continued taking the pills long-term (8-32 months), six eventually showed an improvement in all three types of blood cells, and were able to maintain safe blood counts without needing red blood cell or platelet transfusions. Overall the drug was well tolerated, with few side effects.

The research team in the NHLBI Hematology Branch tested eltrombopag because this drug had previously been shown to boost platelet levels in both healthy people and people with reduced platelets due to hepatitis C infection or immune thrombocytopenia, blood disorders that like aplastic anemia result in low platelet counts and increased risk of bleeding.

The encouraging finding in this study was improvement in red blood cell and white blood cell counts in some aplastic anemia patients, suggesting that the drug can stimulate bone marrow stem cells and perhaps have wider utility than initially predicted.

###

Learn more about this study at: http://clinicaltrials.gov/ct2/show/NCT00922883

Learn more about aplastic anemia at: http://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/

Cynthia Dunbar, M.D., senior investigator in the NHLBI's Hematology Branch and a coauthor on the study, is available to comment on the study's findings and implications for future clinical studies with eltrombopag.

For Dr. Dunbar's complete bio, please visit: http://www.nhlbi.nih.gov/news/spokespeople/dunbar-cynthia.html

For more information or to schedule an interview, contact the NHLBI Communications Office at 301-496-4236 or nhlbi_news@nhlbi.nih.gov.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2012-07/nhla-pds070212.php

martin henderson mlk day golden globes 2012 winners golden globes 2012 red carpet golden globes red carpet nfc championship game martin luther king jr quotes

Oil near $87 ahead of Europe central bank meetings

An oil pump works in the Sakhir, Bahrain, desert oil fields at sunset Tuesday, July 3, 2012. The price of oil jumped more than 4 percent Tuesday to the highest level since May on renewed fears of a military conflict with Iran. (AP Photo/Hasan Jamali)

An oil pump works in the Sakhir, Bahrain, desert oil fields at sunset Tuesday, July 3, 2012. The price of oil jumped more than 4 percent Tuesday to the highest level since May on renewed fears of a military conflict with Iran. (AP Photo/Hasan Jamali)

SINGAPORE (AP) ? Oil fell to near $87 a barrel Thursday in Asia as investors waited for word on whether European central bankers will take measures to boost flagging economic growth.

Benchmark oil for August delivery was down 65 cents at $87.01 a barrel at late afternoon Singapore time in electronic trading on the New York Mercantile Exchange. Crude rose $3.91 to close at $87.66 on Tuesday, the last day the August contract settled in New York.

In London, Brent crude for August delivery was up 1 cent at $99.78 per barrel on the ICE Futures exchange.

Analysts expect the European Central Bank and the Bank of England to either cut lending rates or boost money in circulation at meetings later Thursday. Europe's weak economy and the continent's debt crisis have helped pull oil prices down from $106 two months ago.

The U.S. Energy Department's Energy Information Administration announces its weekly report later Thursday on the latest U.S. crude supply figures.

The American Petroleum Institute said late Tuesday that crude inventories fell 3 million barrels last week while stocks of gasoline fell 1.4 million barrels.

U.S. gasoline "supplies are low, but demand is even lower," energy trader and consultant The Schork Group said in a report.

Growing tensions between Iran and Western powers over that country's nuclear program also have the potential to shake the oil market. Iran said Wednesday that it can destroy nearby U.S. military bases and strike Israel within minutes of an attack on the Islamic Republic.

Europe implemented a ban on buying Iranian crude July 1 and Iran responded by conducting war games exercises that included test-firing several ballistic missiles.

The U.S. and Israel have not ruled out a military strike on Iran's nuclear facilities. Several rounds of negotiations this year have failed to yield an agreement over Iran's development of nuclear power.

"The upside to oil prices based on Iranian threats cannot be underestimated," Schork said.

In other energy prices, heating oil was steady at $2.73 per gallon while gasoline futures were little changed at $2.71 per gallon. Natural gas gained 2 cents at $2.93 per 1,000 cubic feet.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/f70471f764144b2fab526d39972d37b3/Article_2012-07-05-Oil%20Prices/id-f2cb084312bc401bb6bbce8309f0eed7

who do you think you are superpac steve appleton bishop eddie long madonna give me all your luvin video roseanne barr president green party

J&J seeks OK for first drug against resistant TB

FILE- In this Monday, July 17, 2006 file photo, a technician at Ortho-Clinical Diagnostics Inc., a Johnson & Johnson company, works in a "sterile filling" room at the plant in Raritan, N.J. Johnson & Johnson said Monday, July 2, 2012, that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis in more than four decades AP Photo/Mike Derer, File)

FILE- In this Monday, July 17, 2006 file photo, a technician at Ortho-Clinical Diagnostics Inc., a Johnson & Johnson company, works in a "sterile filling" room at the plant in Raritan, N.J. Johnson & Johnson said Monday, July 2, 2012, that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis in more than four decades AP Photo/Mike Derer, File)

TRENTON, N.J. (AP) ? Johnson & Johnson said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis in more than four decades.

The experimental drug, called bedaquiline, also would be the first medicine specifically for treating multi-drug-resistant tuberculosis. That's an increasingly common form in which at least two of the four primary TB drugs don't work.

Tuberculosis, caused by bacterial infection of the lungs and other body areas, is the world's No. 2 killer of adults among infectious diseases.

J&J's Janssen Research & Development unit created the drug, which was tested in several hundred patients with multidrug-resistant tuberculosis in two mid-stage studies lasting for six months. Some patients were studied for about 1 1/2 years.

The company this fall is to begin late-stage testing that will compare bedaquiline to dummy pills over nine months in about 600 patients; each will also take six other drugs that are the standard treatments for tuberculosis. That study is aimed at seeing whether treatment for resistant tuberculosis can be reduced to nine months from the current 18 to 24 months recommended by the World Health Organization.

Roughly one-third of the world's population is estimated to be infected with the bacteria causing tuberculosis. It remains latent in most people for many years but can be activated by another infection or serious health problem.

TB is rare in the U.S. but kills about 1.4 million people a year worldwide, with about 150,000 of those succumbing to the increasingly common multidrug-resistant forms.

Janssen's head of infectious diseases, Dr. Wim Pays, said the company will also apply for approval of bedaquiline in other countries where TB is very common.

The disease is a serious problem in developing countries because it takes so long to cure and many patients stop taking their pills once they begin to feel better. That helps bacteria still alive in the patient to develop resistance to the medicines already taken, making future treatment much more difficult.

J&J shares rose 44 cents to close at $68, just shy of their 52-week high of $68.05 set almost a year ago.

___

Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/bbd825583c8542898e6fa7d440b9febc/Article_2012-07-02-Johnson%20and%20Johnson-TB%20Drug/id-dcf35c2f7f4e49fab9001886185862ba

the secret life of bees full moon amber rose aubrey o day masters live johan santana viktor bout

Extreme heat cancels Brown Deer Kiddie Parade

BROWN DEER ? Due to the heat advisory that has been issued for the Fourth of July, the Brown Deer Kiddie Parade has been cancelled.?

A previously scheduled ?Ice Cream Party? will still be held at 2:00 p.m. near the 1884 Schoolhouse Museum.

The main parade scheduled at 1:30 p.m. will continue as planned. Officials remind spectators and participants to stay hydrated and take precautions due to the extreme heat.

The Brown Deer Pond will be open from noon until 5:00 p.m. as a way to provide relief from the warm weather.?

The fireworks display remains as scheduled at 9:30 p.m. Private fireworks are illegal within the Village of Brown Deer.

CLICK HERE for a complete schedule of the 4th of July events for Brown Deer.

For additional information, please feel free to contact either the Village Manager?s Office at (414) 371-3050 or the Park and Recreation Department at (414) 371-3070.

Source: http://northwest.fox6now.com/news/news/127693-extreme-heat-cancels-brown-deer-kiddie-parade

tori spelling marion barber marion barber syracuse ohio state girl with the dragon tattoo ohio state basketball

'Bristol Palin: Life's A Tripp': Bristol Surprised By Sarah Palin Impersonator (VIDEO)

After under-performing in the ratings, Lifetime moved "Bristol Palin: Life's a Tripp" (Tue., 11 p.m. ET on Lifetime) to a later time slot, in the hopes it can maybe scrounge up some more viewers at a less competitive time.

This week, Bristol came face to face with a woman who impersonates her mother. Tina Fey may be the most famous Sarah Palin impersonator, but there are plenty others out there. This one even looked a lot like the former vice-presidential candidate.

The similarity was so striking, that a man walking by thought she was Sarah Palin, and started talking about how he'd supported her in the last election. But rather than set the record straight for him, the woman pretended she was Sarah Palin, right in front of Bristol.

Bristol was shocked that she didn't break the illusion, but maybe she just didn't want to shatter what was clearly a big moment for the man. At least until he or one of his friends he told about the encounter happens to see the show and lets him know he was duped.

"Bristol Palin: Life's a Tripp" airs Tuesdays at 11 p.m. ET on Lifetime ... unless they move it again.

TV Replay scours the vast television landscape to find the most interesting, amusing, and, on a good day, amazing moments, and delivers them right to your browser.

Related on HuffPost:

"; var coords = [-5, -72]; // display fb-bubble FloatingPrompt.embed(this, html, undefined, 'top', {fp_intersects:1, timeout_remove:2000,ignore_arrow: true, width:236, add_xy:coords, class_name: 'clear-overlay'}); });

Source: http://www.huffingtonpost.com/2012/07/04/bristol-palin-lifes-a-tripp-sarah-palin-impersonator-video_n_1648357.html

planetary resources mothers day gift ideas natalee holloway scotty mccreery megan fox pregnant metta world peace suspension apple earnings report

The Reign of Dragons

The Reign of Dragons

There are three ruling powers. Each are at each other's throats most of the time. However, there is a darkness brewing that threatens to tear apart each and everyone of them if it isn't stopped.

Owner:

Game Masters:

This topic is an Out Of Character part of the roleplay, ?The Reign of Dragons?. Anything posted here will also show up there.

Topic Tags:

online roleplay roleplay online -->

HTML, for websites and MySpace:

BBcode, for forum posts and signatures:

--> Forum for completely Out of Character (OOC) discussion, based around whatever is happening In Character (IC). Discuss plans, storylines, and events; Recruit for your roleplaying game, or find a GM for your playergroup.
This is the auto-generated OOC topic for the roleplay "The Reign of Dragons"

You may edit this first post as you see fit.

There is Magic all around, you just have to look to see it...

User avatar
Qaida
Member for 0 years



I will have more tomorrow, I still have pictures to add and some editing to do. But, don't wait for me :) bring on the characters!!

User avatar
Qaida
Member for 0 years


OMG! I squeed so hard when I saw this. I am so making a char!! I think I am leaning towards having a black dragon but I will have to see. :)

Stupidity is the only universal capital crime.

Someone once asked me, 'Why do you always insist on taking the hard road?' I replied, 'Why do you assume I see two roads?'

There is no limit to how bad things can get.

Beware the person who has nothing to lose.

Depression is merely anger minus the enthusiasm.

Let no one think I gave in.

I chose to quit.

User avatar
Selene Durlan
Member for 1 years


I'll be joinin' now. :D

The people shouldn't be afraid of their government.
The government should be afraid of their people.

Image

User avatar
LuminousKing
Member for 0 years



Post a reply

RolePlayGateway is a site built by a couple roleplayers who wanted to give a little something back to the roleplay community. The site has no intention of earning any profit, and is paid for out of their own pockets.

If you appreciate what they do, feel free to donate your spare change to help feed them on the weekends. After selecting the amount you want to donate from the menu, you can continue by clicking on PayPal logo.

Who is online

Registered users: Abraxas*, AceofSpade, Aniihya, Aphira, Arabella13*, Arceius*, Arluar, AvengerSpirit*, BrandedOne, Breyerluv, Brock10*, Broken Bottles*, Bromander Shepard*, CaesarTheSeventh*, Calvazara*, CielleAmor, Cienpher*, cmpuncle, Colonel_Masters*, cool4345, Cooper*, Crooked Thoughts, CutieLol111, Dante Angelico*, DarknessUndying, darkune*, Digital_Muse*, DumbDora*, DuskFire35*, DustAndEchoes*, Entity of Sin*, Evita*, Firebird18*, flickery, flieslikeabrick, Free_Polity*, Gamer_Templar*, Gasmask*, Geekly*, Google [Bot], Google Adsense [Bot], Google Feedfetcher, gperry88*, Hinasil*, Hingyou*, HitoriRaven*, Hydrall*, Hypnosis, Imehal, JacintoRain*, jackrules158*, Jadeling Hawkins*, jazzanah*, JimmyKnoles*, JimmyTheRat*, Jinx911, Kai*, kathrin, Keita*, Korrye*, KulasLightShadow*, Kuukakulily*, Kyren.Laili*, Lady Inali*, Lifecharacter*, Lloyd999*, Lucian1549, LuminousKing*, Lyndie*, Majestic-12 [Bot], Mariofox*, masato22*, MaxStokes*, Mr_Doomed*, MSNbot Media, Nekohina, nightwolf, NorthernSoul, oetunianne*, parallelzero, Patcharoo*, peace_love_dance, Penfold*, PINKanime*, PoorImpulseCtrl, Popuph8r, Porecomesis*, PreachingLegionary, Princess Awinita*, R.T.M.X., raindrops_autumn, ReaperGirl4*, RebornAncient12*, ROFLMAO FTW, Romaneck, Ropeburn*, Rulke, Sacred Wolf, Script*, Selene Durlan, Sench*, shadowty*, Shynx, silentawakening*, SkullJester, Slump, Sneakyrio*, Sokka25*, spivstars*, Stark Contrast, Stella11, stormwolf321*, Sweet Angel Jocelyn, T1ra, TechScience, TemplarWarden*, The Cynic, The Great Thundorz*, TheFinalOne*, TheMarchBaby23*, Tiko*, Tom Ice*, tornadofan2*, Varanus*, Vestiline*, VitaminHeart*, WadeJackel*, Welcome Home*, whscorbin, WordSail, Xiiver, XxEvil1xX*, XxYuraxX*, Yahoo [Bot]

Source: http://feedproxy.google.com/~r/RolePlayGateway/~3/EfTLL__YkEk/viewtopic.php

burger king mary j blige google project glass google goggles one tree hill projectglass stock act new york auto show